Dare Bioscience offers women’s reproductive health devices, therapeutics and diagnostics and provides contraception, vaginal health, pain and fertility products.
Dare Bioscience acquired Cerulean Pharma, a nanotechnology-based therapeutics company in 2017. In 2018 Dare Bioscience entered a merger with Pear Tree Pharmaceuticals that includes securing rights to PT-101, a vaginal formulation of tamoxifen as a treatment for vulvar and vaginal atrophy in hormone-receptor-positive breast cancer patients.
DARE-BV1 is a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application. Other products in clinical development include Ovaprene, a non-hormonal monthly contraceptive ring and SST-6007 (5% Topical Sildenafil Citrate Cream), containing the same active ingredient in Viagra in a proprietary cram formulation for treating Female Sexual Arousal Disorder.
Dare Bioscience's segmented Intravaginal Ring (IVR) technology is developed for sustained drug delivery of one or more drugs at variable dosages for up to four weeks. The company is developing the DARE-HRT1 product candidate which is a combination of bio-identiacal estradiol and bio-identical progesterone IVR for hormone replacement therapy. In addition the product candidate DARE-FRT1 is a bio-identical progesterone IVR for the prevention of preterm birth and for fertility support as part of an in vitro fertilization plan.